SPONSOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Total Trials
3
Recruiting
3
Phases
Phase 2
Conditions studied: Head Neck TumorsNeuroendocrine TumorsSoft Tissue SarcomaRare CancerVaccinationBreast CancerLymphomaAdvanced Prostate CancerAdvanced Breast CancerMonoclonal Gammopathy of Undetermined Significance
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
How many clinical trials has Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, of which 3 are actively recruiting participants. These trials cover conditions including Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS research focus on?
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS clinical trials span Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer, Vaccination, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS clinical trial?
To participate in a Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS trials with current recruitment status updated daily.
Clinical Trials by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT04166006 Phase 2
Recruiting
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Head Neck Tumors
NCT04590560
Recruiting
What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?
Breast Cancer
NCT06895291
Recruiting
Whole Body MRI in Oncology
Lymphoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology